Accession Number: | 0001192482-19-000256 |
Date: | 2019-05-13 |
Issuer: | RECRO PHARMA, INC. (REPH) |
Original Submission Date: |
HENWOOD GERALDINE
C/O RECRO PHARMA, INC.
490 LAPP ROAD
MALVERN, PA 19355
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-05-13 | M | 123,500 | a | $2.47 | 342,947 | direct | ||
COMMON STOCK | 2019-05-13 | S | 123,500 | d | $8.89 | 219,447 | direct | ||
COMMON STOCK | 2019-05-13 | S | 21,306 | d | $8.89 | 198,141 | direct | ||
COMMON STOCK | 2019-05-13 | 0 | $0.00 | 50,000 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 2.47 | 2019-05-13 | deemed execution date | M | 123,500 (d) | 2024-12-17 | common stock 123,500 | $2.47 | 0 | direct |
ID | footnote |
---|---|
f1 | the price reported in column 4 is a weighted average price. the shares were sold in multiple transactions at prices ranging from $8.78 to $8.98, inclusive. the reporting person undertakes to provide recro pharma, inc., any security holder of recro pharma, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 3 to this form 4. |
f2 | the sale reported in this form 4 was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
f3 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $8.84 to $8.92, inclusive. |
f4 | the shares subject to this option are fully vested and exercisable. |